Monitor cash runway and clinical trial progress for (Z)-endoxifen; the offering provides near-term capital but dilutes existing shareholders by ~15% on the upfront portion, with further dilution if warrants are exercised.
Price Chart
Executive Summary
Atossa Therapeutics reported Q2 2026 net loss of $8.5M ($0.95 per share), beating consensus of $1.04 loss per share by 8.7%. Cash fell to $26.1M from $41.3M at year-end. A registered direct offering raised $4.5M upfront with potential $12M more from warrants, adding dilution but extending runway.
Key Financial Metrics
Key Facts
- Q2 2026 net loss $8.5M, EPS -$0.95 vs consensus -$1.04 (beat by 8.7%)
- Cash and equivalents $26.1M at June 30, 2026, down from $41.3M at Dec 31, 2025
- Registered direct offering raised $4.5M upfront; warrants could add $12M
- No revenue; pre-revenue clinical-stage biopharma
- R&D expenses $4.9M in Q2 2026, down 11% YoY
Financial Impact
Net loss $8.5M, EPS beat by 8.7%, cash burn $15.2M in H1 2026, offering provides $4.5M upfront with $12M potential
Risk Factors
- Cash burn may require further capital raises within 12 months
- Dilution from warrant exercises could exceed 30% of current shares
- Clinical trial failure risk for (Z)-endoxifen
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302845837 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 8-K | $2.44 | awaiting T+60 | — | $2.45 (+0.41%) |
Sep 29, 2026 27d ago | 8-K | $1.99 | awaiting T+60 | — | $2.45 (+23.12%) |
Sep 18, 2026 5w ago | 8-K | $2.25 | awaiting T+60 | — | $2.45 (+8.89%) |
Aug 7, 2026 11w ago | 8-K | $2.36 | awaiting T+60 | — | $2.45 (+3.81%) |
Aug 7, 2026 11w ago | Press Release | $2.36 | awaiting T+60 | — | $2.45 (+3.81%) |
Jun 12, 2026 19w ago | 424B5 | $2.46 $2.52 | ▼ −2.24% | ▲ +1.03% | $2.45 (+0.41%) |
Apr 16, 2026 27w ago | 8-K | $5.77 $2.40 | ▼ −58.41% | ▼ −65.45% | $2.45 (−57.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers